Abstract: An exhaust gas turbocharger may include a shaft mounted in a bearing housing carrying a compressor wheel and a turbine wheel. The shaft may include a sealing bush arranged on the shaft in a rotationally fixed manner. The sealing bush together with a bearing housing cover may at least partially delimit an annular oil centrifuging space arranged coaxially to the sealing bush. The bearing housing cover may include a guiding nib located radially outside the sealing bush partially covering the sealing bush in axial direction. The guiding nib may be configured to guide oil separated in the oil centrifuging space onto the rotating sealing bush. The rotating sealing bush may be configured to direct the oil into the oil centrifuging space in response to centrifugal force creating an oil swirl.

Abstract: An exhaust gas turbocharger may include a shaft mounted in a bearing housing carrying a compressor wheel and a turbine wheel. The shaft may include a sealing bush arranged on the shaft in a rotationally fixed manner. The sealing bush together with a bearing housing cover may at least partially delimit an annular oil centrifuging space arranged coaxially to the sealing bush. The bearing housing cover may include a guiding nib located radially outside the sealing bush partially covering the sealing bush in axial direction. The guiding nib may be configured to guide oil separated in the oil centrifuging space onto the rotating sealing bush. The rotating sealing bush may be configured to direct the oil into the oil centrifuging space in response to centrifugal force creating an oil swirl.

Abstract: Disclosed is a method for producing virus-like particles (VLP) that comprises the steps of (a) transfecting a mammalian cell line with several independent vectors, including (1) a vector containing at least a substantial part of the M gene from Rift Valley Fever Virus, (2) a vector containing at least a substantial part of the L gene from Rift Valley Fever Virus, (3) a vector containing at least a substantial part of the N gene from Rift Valley Fever Virus and (4) a vector containing a multicloning site flanked by the non-coding 5?- and 3?-ends of the L-, M- or S-segment of Rift Valley Fever Virus, and (b) culturing the transfected mammalian cell line under suitable conditions and obtaining the VLPs from the supernatant of the transfected cultured cell lines. The so-obtained VLPs can be used for vaccination and in methods for testing the antiviral activity of compounds.